Angiogenesis inhibition with bevacizumab and other agents of this class are showing
significant activity in a variety of cancers. In prostate cancer, the single agent activity has
been low, but the addition of these agents to chemotherapy may be the area in which they
provide their greatest clinical benefit. An ongoing study conducted by the Cancer and
Leukemia Group B will test this approach in men with metastatic hormone refractory prostate
cancer. Future studies may test the efficacy of anti-angiogenic strategies in earlier stage …